Board of Directors

About PHI

Phase Holographic Imaging AB (PHI) provides researchers in academia and the life sciences industry with products for live-cell kinetic studies. PHI’s time-lapse cytometer, the HoloMonitor® system, is based on our core technology holographic microscopy. Since introducing the first instrument in 2011, PHI now offers a range of products for the label-free, long-term quantitative analysis of living cell dynamics, circumventing the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors.

The HoloMonitor system is a versatile tool providing detailed information about the life cycle and behavior of living, or dying, cells to scientists all over the world. Focus areas include basic cell research as well as the development of more efficient treatment strategies for cancer and other diseases. Committed to promoting the science and practice of time-lapse cytometry, PHI is continuously developing new products and applications in close collaboration with scientific expertise.

The Greek letter φ (phi) often denotes the phase of a wave. PHI’s products create holographic phase images – hence, the logo and our company name, Phase Holographic Imaging.

Background

Modern drug research is based on experiments performed on cultured cells. Living cells are translucent and therefore difficult to see in an ordinary light microscope without stains or labels. Many of the methods used to visualize cells are destructive. This has curiously meant that life’s smallest building block – the cell – is generally studied only when it is dead. 

The concept of holographic microscopy

PHI’s time-lapse cytometers are designed to non-invasively explore the kinetics of cellular responses, rather than just providing snapshots the way traditional endpoint assays do. PHI’s time-lapse cytometers are based on a novel microscopy technology – holographic microscopy – that automatically analyzes living cells in ways not previously possible. 

PHI has been granted over 10 patents and has a portfolio of further applications in the pipeline. This new digital capability will fundamentally change light microscopy and thus humanity’s ability to observe living cells.

History – Development of a successful product line

After successful collaboration between the Competence Center for Circuit Design (CCCD) at Lund University and PHI’s founders resulting in M1, the first prototype of the HoloMonitor product line, PHI was founded in 2004.  

PHI’s first commercial product, the HoloMonitor M3, was launched on the international market in 2011. The HoloMonitor M3 (red and grey instrument in the photo above) is a bench-top time-lapse cytometer equipped with a motorized stage and variable magnification. In the same year, PHI received a governmental grant from Vinnova to develop the fourth HoloMonitor generation. 

As a result, PHI’s second product, the HoloMonitor M4 (blue and white instrument in the photo above), was internationally launched in early 2013. The HoloMonitor M4 allows for the time-lapse analysis of living cells directly in the cell incubator in which they are being cultured. 

Today, HoloMonitor systems are in use in Europe, North America, Asia, and Australia and their uses and benefits have been described in a long series of peer-reviewed scientific publications.

Management

Peter Egelberg

CEO
Born 1963
peter.egelberg@phiab.se
Tel: +46 (0)46-386081
Mobile: +46 (0)703-194274

Arne Bojesson

CFO
Born 1951
arne.bojesson@phiab.se

Jonas Bergkvist

CTO
Born 1971
jonas.bergkvist@phiab.se
Tel: +46 (0)46-386082

Liselotte Nilsson

Head of Marketing
Born 1970
liselotte.nilsson@phiab.se

Håkan Rosvall

Head of Sales
Born 1979
hakan.rosvall@phiab.se
Tel: +46 (0)46-386089
Mobile: +46 (0)73-0717424

Board of Directors

Klas Cramborn

Chairman of the Board
Born 1949. Former CEO of Dentsply IH, Russia. Various senior positions at Ferring Pharma­ceuti­cals, Mölnlycke Healthcare, HemoCue and AstraTech.
LinkedIn

Leland Foster

Board Member Born 1946. Former Chief Scientist of Thermo Fisher Scientific. Former CEO of Fisher Scientific Bioscience Group, Perbio Science and HyClone Laboratories. LinkedIn

Johan Hyllner

Board Member
Born 1962. Chief Scientist (CSO) of the Cell and Gene Therapy Catapult, UK. Former CSO at Cellectis (stem cells), Cellartis, Vitrolife Sweden and SQC.
LinkedIn

Mats Lundwall

Board Member
Born 1948. Former CEO of Cellartis Sweden and UK, Santaris Pharma AS, Ferring Pharmaceuticals and Eurodiagnostica AB/BV.
LinkedIn

Jan Richardsson

Board Member


Born 1960. CEO of Dignitana AB. Former V.P. of sales at Nederman AB and HemoCue AB. LinkedIn

Maria Morin

Board Member
Born 1974. VP Human Resources & Corporate Communications at CellaVision AB (publ), previous positions at Gambro AB, Perstorp AB and DaimlerChrysler A/S.
LinkedIn

Linda Neckmar

Board Member
Born 1973. M Sc in Chemistry and VP EMEA & APAC at Probi AB (publ). Previsously Bioinvent International AB.
LinkedIn

Anne-Christine Egelberg

Suppleant
Born 1963. Independent consultant, financial reporting, controlling and accounting services.
LinkedIn

Advisors

Ron Lowy

Former CEO of Biosciences Group Thermo Fisher Scientific.

 

Cindy Collins

CEO of In Vitro Diagnostics and Research & Applied Markets GE Healthcare. Former CEO of GenVec and Group V.P. of Cellular Analysis Beckman-Coulter.

 

Elena Holden

Former CEO of the pioneer of laser scanning cytometry – CompuCyte, Boston USA.

Career

PHI is growing and always interested in finding new talented individuals – from new graduates to experienced professionals – to join our team. You are welcome to send your CV to info@phiab.se.  Write "unsolicited application" in the subject line.

 

When there are open positions they are posted below.

Partnership

PHI collaborates with a range of centers of excellence, each running first-class research programs in which HoloMonitor technology plays an important role. Joint programs include activities intended to establish the best practices and validate the most useful HoloMonitor parameters:

  • Develop novel applications based on HoloMonitor technology 
  • Establish a network of collaborators utilizing holographic imaging cytometry
  • Improve methods for the clinical diagnosis of cancer

Results from our partner centers of excellence are presented at scientific meetings and published in peer-reviewed scientific journals. We also organize technology symposia and hands-on laboratory courses.